CSPC Pharmaceutical Group Limited · HKEX:1093
CSPC Pharmaceutical — H1 2025 Earnings Presentation
38 slides from CSPC Pharmaceutical's earnings presentation, August 2025
Slide 1: 2025 Interim Results Presentation
Mo#®keaBRaAo CSPC CSPC PHARMACEUTICAL GROUP LIMITED (Stock Code : 1093) 2025 Interim Results Presentation Aug. 2025 4) ON
Slide 2: R&D, Manufacturing and Commercialization Capabilities
R&D Capabilities Manufacturing Capabilities 10+ Production bases for pharmaceutical products + Nano formulation production capacity of 20M doses/year; Biologics fermentation capacity of 250,000L I + Chemical drugs production capacity of OSD ~30B tablets/year, production capacity of injection ~3B dos
Slide 3: 2025H1 Updates
Lo L 3 2025H1 Updates Regulatory Updates new drugs approved: + Enyitan + Shanzeping + Meiluotai breakthrough therapy designation: + SYS6010 for injection (EGFR ADC) + Sirolimus for injection (albumin-bound) + JSKNOO3 + JMT101 | Major Clinical Trial Progress d7 i IND approvals : * China(28) North Ame
Slide 4: Remarkable Success of the R&D Pipeline
| Remarkable Success of the R&D Pipeline ——— BB innovative products launched since 2021 Hi Milestones: The year of 2025 provide continuous growth momentum ; : . Approved for marketing a _ : a | roast Amphotericin B liposome DBPR108 Irinotecan liposome 2021-2022 — | a (the U.S.) T2DM 1L Pancreatic ca
Slide 5: Financial Highlights
Financial Highlights
Slide 6: Financial Highlights
r Financial Highlights Unit: RMB’ M 25H1 24H1 Change Revenue 13,273 16,284 -18.5% Gross profit 8,710 11,655 -25.3% Gross profit margin 65.6% 71.6% -6.0 pp R&D expenses 2,683 2,542 +5.5% Reported profit attributable to shareholders of the Company 2,548 3,020 -15.6% Underlying profit attributable to s
Slide 7: Revenue
r Revenue = a Revenue by product category Revenue by therapeutic area Unit: RMB’ M 25H1 24H1 Change 25H1 24H1 Change Nervous system 3,755 5,236 -28.3% | ieicieisincininelel inininisisinins wninniniiens teiciieinaial i Oncology 1,051 2,683 -60.8% || Finished drugs 10,248 13,549 -24.4% H i L Anti-infe
Slide 8: Operating Profit
| Operating Profit Unit: RMB’ M 25H1 24H1 25H1 24H1 Change aan GPM Change Finished drugs 2,392 3,489 -31.4% 23.3% 25.7% -2.4 pp Bulk vitamin C 181 68 +167.6% 15.1% 6.9% +8.2 pp Bulk antibiotics 145 186 -22.0% 16.5% 21.4% -4.9 pp Fi ti | Food and Pde aaa 209 175 +19.7% 22.0% 19.9% +2.1 pp Note: Certa
Slide 9: Overview of Clinical Development for Key Products
02 Overview of Clinical Development for Key Products
Slide 10: Oncology: Innovative Nano-Formulation Platform, Paclitaxel Market
r Oncology: Innovative Nano-Formulation Platform, unlocking the Paclitaxel Market== ( * ' Indication Phi Phil Phill NDA ' : Docetaxel for injection (aloumin- 224 Gastric Cancer bound)-Globally Exclusive ees srexctere ) — aby 23L Pancreatic ; ' ' Cancer enrolling 2026 ' ' 1 albumin (VS Optimal H ' su
Slide 11: Oncology: HER2 BsAb - KN026
— | Hi Oncology: HER2 BsAb - KN026 — Overview of Clinical Development for KN026 Dual blockade of HER2 Il and IV epitopes @GICueu Treatment IND Phill Phill BLA Breast cancer f demeh arate 4L breast cancer Co HB1801 (n-885) vetastizumad, petuzunad + TTT «2028 7 gm & docetaxel albumin wl us of WAG Neoa
Slide 12: Oncology: JSKN003 HER2-ADC
[my Oncology: JSKNO03 HER2-ADC = in | Heo] Glycan-specific conjugation platform All population 63.0% 7.7m 2025 Ovarian Platinum Rx 5 ASCO cancer resistance [to a po Gein .e) gy IHC 1- 3+ 18 72.2% 9.4m ASCO Breast oy 2025 anced 22L HER2+’ 30 73.3% # GC/GEJ 27 63.0% 9.6m ASCO za HCae CRC 21 61.9% 13.7
Slide 13: Oncology: JMT101 (EGFR Monoclonal Antibody)
° — | wi Oncology: JMT101 (EGFR Monoclonal Antibody) —— Indication Phase Il Phase Ill Remarks ee Q 1 H { EGFR 20ins NSCLC(1L) JMT101+0simertinib vs Platinum-based chemotherapy 2026 BLA i i ' i i i H | EGFR mutation NSCLC (1L) JMT101+ osimertinib vs osimertinib 2027 BLA i H | | ins. (nn : O High affi
Slide 14: JMT101+SG001+Irinotecan vs Regorafenib
r JMT101+SG001+ Irinotecan vs Regorafenib —— Results of a randomized, controlled, open-label Phase II trial for the treatment of advanced colorectal cancer (3L+) -3.2 (-20.3, 14.0) SS 10.2 (-12.1, 32.5) Data cut-off date: Jan 24, 2025. 22 ASCO (Arm A, n=36) (Arm B,n=35) (Arm C, n=35) Events, 18 20 2
Slide 15: Oncology: SYS6010 EGFR ADC
[gy Oncology: SYS6010 EGFR ADC — Treatment Phi Phil Phill Remarks SY$6010 vs Platinum- oR BBB vecrrmunscic 6 = 2026 BLA @Q based chemotherapy Phase Ib/lll SYS6010+Osimertinib ea 4L EGFRmut NSCLC = ae k= ==> Phase Ib vs Osimertinib under follow up EGFR wt NSCLC iam) and other advanced solid + SYS6010
Slide 16: Oncology: Simmitinib - Entering Pivotal Trial for ESCC
r Oncology: Simmitinib — Entering Pivotal Trial for ESCC ——— Simmitinib is a Novel Tyrosine Kinase Inhibitor Targeting FGFR1-3, KDR and CSF-1R Approximately 240,000 new EC cases are reported annually in China, with ESCC accounting for 90% 8 Phase 1 study of simertinib monotherapy ne for advanced sol
Slide 17: Immunity: SYHX1901 - Autoimmune Diseases
Immunity: SYHX1901—Covering a Variety of Autoimmune Diseases Multi-target = CONG inhibition See CONC JAK1 AMSTERDAM JAK3 3h bm Senkanrber TYK2 Potential Syk inhibitory Efficacy and safety of SYHX1901 in moderate-to-severe plaque psoriasis: Fryers a multicenter, randomized, double-blinded, placebo-co
Slide 18: Immunity: CM326 - Asthma Populations
Immunity: CM326 — Covering Asthma Populations Regardless of Phenotype== Indicat Phase! Phase Il Phase Ill { Moderate-to-Severe | Phase II finished f Asthma i i Chronic ‘ | Rhinosinusitis with Phase II follow-up > H Nasal Polyps i H | Phase II/ Ill Hl if COED | under initiation \ \. va Registration C
Slide 19: Immunity: BCMA CAR-T for Autoimmune Diseases
Immunity: BCMA CAR-T — A New Therapy for Drug-Free Remission in — 4 . Autoimmune Diseases Indication it Phase! Phase Il IND approval Systemic Lupus Phase | dose escalation \ Erythematosus + cohort expansion maats ! Malignant ' plasma cell H Myasthenia Gravis peat dose oan oman : Registration Categor
Slide 20: Metabolism: GLP-1 series products
rr Cardiovascular and endocrine Metabolism: GLP-1 series productS===m Clinical development and layout of GLP-1 series products Indication Phase | Phase Il Phase III TG103 (Fc-GLP1) (Class 1) Obesity T2DM Semaglutide Injection (Class 2.2) Obesity T2DM Others Semaglutide Long-actin. : s u Enrolling In
Slide 21: Metabolism: siRNA series products
r Cardiovascular and endocrine Metabolism: SiRNA series products===m CNS Indicati Phase | Phase II Phase Ill $e PCSK9 SiRNA Expected to be Adult primary hypercholesterolemia launched by the end \ MUSCLE and mixed dyslipidemia of 2025 LUNG eae LP (a) SiRNA UVER ee Hyperlipoprotein A-emia sit KIDNEY ;
Slide 22: R&D Pipeline
R&D Pipeline
Slide 23: R&D Overview
[gy R&D Overview R&D Centers& Projects Technology Platforms + 5 R&D centres located in + 8 national science & technology China & the U.S. qualifications + Approx. 200 Innovative drugs + 2 national key labs and new formulations * 8 innovative R&D platforms Intellectual Property + 2282 patent applicat
Slide 24: Innovative R&D Platforms
ir 8 Innovative R&D Platforms mRNA vaccine Nano- formulation > Mitoxantrone Hydrochloride Liposomes Albumin-bound docetaxel Irinotecan liposomes Cisplatin micelle vvv Antibody & Fusion protein ee i ee > JMT203 (GFRAL) > JMT106 (GPC3/IFNa) > JMT206(ActRIIA/B) > JMT108(PD-1/IL-15) > Covid-19 mRNA vacc
Slide 25: Key Innovative Products in Clinical Stage
[ gy Key Innovative Products in Clinical Stage Phase II/IIl Pivotal Trial Phase | Nei JMT1 TNFR2 BsAb Phase II (POC) sys6002 JMT101 Nectin-4 ADC EGFR mAb NDA/BLA Inotecen liposome DP303C $¥S6010 TL Metastatic HER2 ADC EGFR ADC encreatc cancer JMT 203 SYS6011 JMT601 KNO: JMT103 ens Albumin-bound PDI
Slide 26: R&D Pipeline - Biological Agents
R&D Pipeline--Biological Agents 3 commercialized, 2 BLA filed, 8 under pivotal trial stage, > 15 under pre-clinical stage — Including various forms of drugs such as antibody drugs, cell therapies, and Antibody-Drug Conjugates (ADCs) Major candidates Target Type Phase | Phase Il Phase II/III NDA/BLA
Slide 27: R&D Pipeline - Biological Agents
[gy R&D Pipeline--Biological Agents —_—— Major candidates Target Type Phase! Phase Il Phase II/Ill NDA/BLA Launch JMT103 RANKL mAb Launch: GCTB; Under clinical development: bone metastasis (PhIll) . osteoporosis JMT101 EGFR mAb NSCLC, Colorectal cancer ALMBO0168 CX43 Agonist mAb Bone cancer, cancer
Slide 28: R&D Pipeline - New Formulations
R&D Pipeline--New Formulations 3 commercialized, 4 NDA filed, 2 under pivotal trial stage, > 5 under clinical development stage —Including various forms of drugs such as liposomes, albumin and nanocrystals Phase! Phase Il Phase II/III NDA/BLA Launch Major candidates Type ies hydrochloride liposome N
Slide 29: R&D Pipeline - Small Molecule Drugs
° ° — R&D Pipeline--Small Molecule Drugs — 1 commercialized, 2 NDA filed, T under pivotal trial stage, > 10 under clinical development stage Major candidates Target Type Phase | Phase Il Phase IM/III NDA/BLA Launch Pregabalin extended- faleacotablets y-GABA analogue STurlmurestl-m Diabetic periphera
Slide 30: Common Generics Launch Plan
ir Common Generics Launch Plan 20+ generic drugs are expected to be approved during the years 2025-2026; Additionally, approximately 30 projects currently in the pharmaceutical research phase. Peramivir Injection Regorafenib tablets Alprazole enteric ee oe A i | rT ic- Tand itrat lansoprazole enteri
Slide 31: BD & ESG
BD &ESG
Slide 32: BD Strategic Layout and Path of Advancement
rr BD Strategic Layout and Path of Advancement — — a Deepen the BD strategy and build an international BD ecosystem Licence out in 2025 Al SYH2086 GLP-1 eal BG we SYS6005 : : _. ’ ’ ROR1 ADC Irinotecan Liposome Injection Strategic collaboration ep erpsr Cipla Astrazeneca 2 Mazrigal Time: 2025.2 Time
Slide 33: Aim to Become an ESG Leader in Pharmaceutical Industry
[gy Aim to Become an ESG Leader in Pharmaceutical Industry=—= 2024 Key Environmental Protection Data “The emission reduction target is based on the emission in 2017 Greenhouse gas emissions per Emission of non-hazardous Discharge of hazardous unit of revenue waste (general solid waste) per waste per
Slide 34: Appendix: Product Overview
Appendix: Product Overview
Slide 35: Finished Drugs Overview by Therapeutic Areas
[my Finished Drugs Overview by Therapeutic Areas Digestion & Others metabolism 8.05% 5.76% | \ Respiratory system—__ 6.27% Total : — 9.173B Cardio- ae ae vascular (excluding licence fee 9.47% income) Anti-infective “ 18.06% Oncology 11.45% Nervous system Oncology Anti- infective Cardio- vascular Res
Slide 36: Innovation achievements: Overview of Key Products
Innovation achievements: Overview of Key products === . New Formulations and Innovative drugs Biosimilar Drugs ih" 4 = a Mingfule | Duometsu | = Duoen: ee Butylphthalide Recombinant human TNK PEG-rhG-CSF Doxorubi Hydrochloride Irinotecan hydrochloride soft capsules and tissue-type plasminogen inject
Slide 37: Bulk Products, Functional Food and Other Businesses
[gy Bulk Products, Functional Food and Other Businesses=———=—= \ 4 Bulk vitamin C Bulk antibiotics * Major products: vitamin C, vitamin C - + Major products: 7-ACA (intermediate), cefazolin + sodium, vitamin C - calcium and sodium, penicillin potassium, penicillin sodium, granular vitamin C azithrom
Slide 38: Support / IR contact
38 SUPPORT GUIDANCE, 7 E-mail Address of CSPC IR Team: [email protected] IR official website: Eigheaenal
CSPC Pharmaceutical Group — H1 2025 Earnings Presentation on 6ix